HSP90 Inhibitor PU-H71 in Combination With BH3-Mimetics in the Treatment of Acute Myeloid Leukemia [PDF]
Targeting the molecular chaperone HSP90 and the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML).
Ulrike Bacher +2 more
exaly +8 more sources
The Anti-Myeloma Activity of a Novel Purine Scaffold HSP90 Inhibitor PU-H71 Is via Inhibition of Both HSP90A and HSP90B1 [PDF]
Background Heat shock protein 90 (HSP90) inhibitors have emerged as a promising class of anti-cancer drugs in both solid and hematologic malignancies.
Saad Z Usmani +2 more
exaly +7 more sources
Epichaperome Inhibition by PU-H71-Mediated Targeting of HSP90 Sensitizes Glioblastoma Cells to Alkylator-Induced DNA Damage [PDF]
Background: Targeted therapies have been largely ineffective against glioblastoma (GBM) owing to the tumor’s heterogeneity and intrinsic and adaptive treatment resistance.
Pratibha Sharma +2 more
exaly +5 more sources
PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond [PDF]
Heat shock protein 90 (HSP90) is a pivotal molecular chaperone with multifaceted roles in cellular health and disease. Herein, we explore how HSP90 orchestrates cellular stress responses, particularly through its partnership with heat shock factor 1 (HSF-
Sameh Saber +16 more
doaj +4 more sources
Synthesis and Evaluation of Cell-Permeable Biotinylated PU-H71 Derivatives as Tumor Hsp90 Probes [PDF]
The attachment of biotin to a small molecule provides a powerful tool in biology. Here, we present a systematic approach to identify biotinylated analogues of the Hsp90 inhibitor PU-H71 that are capable of permeating cell membranes so as to enable the ...
Gabriela Chiosis +2 more
exaly +4 more sources
In Vitro Purging of Acute Lymphoblastic Leukemia (B-ALL) Cells with the Use of PTL, DMAPT, or PU-H71. [PDF]
Acute lymphoblastic leukemia (ALL) is a hematopoietic disorder that mainly affects the child population, and it is characterized by the presence of lymphoid progenitor or precursor cells with different genetic alterations.
Ortiz-Reyes AE +11 more
europepmc +4 more sources
Mutation of Framework Residue H71 Results in Different Antibody Paratope States in Solution [PDF]
Characterizing and understanding the antibody binding interface have become a pre-requisite for rational antibody design and engineering. The antigen-binding site is formed by six hypervariable loops, known as the complementarity determining regions ...
Monica L. Fernández-Quintero +4 more
doaj +3 more sources
FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia [PDF]
Targeting the FLT3 receptor and the IL-1R associated kinase 4 as well as the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML).
Katja Seipel +3 more
doaj +2 more sources
HSP90 inhibitörü PU-H71’in ve radyoterapi ile kombine uygulamasının metastatik meme kanseri üzerine etkisinin araştırılması [PDF]
HSP90 (Isı Şok Proteini 90) birçok hücresel proteinin stabilizasyonunu sağlamaktadır. Stresli durumlarda ekspresyonu artan HSP90 hücresel proteinleri degredasyondan korur. HSP90'nın ekspresyon profili normal ve malign hücrelerde farklılık göstermektedir.
Kale, Şule
core +3 more sources
PU-H71, a Heat shock protein 90 (Hsp90) inhibitor, has yielded therapeutic efficacy in many preclinical models and is currently in clinical trials. Carbon-ion radiotherapy (CIRT) has provided successful tumor control; however, there is still a room for ...
李 惠子 +15 more
core +4 more sources

